On 15 July 2026 the European Commission approved a once-daily tablet version of Wegovy for weight management. It is the first GLP-1 you can swallow that's licensed for weight loss anywhere in the EU, and because EU approvals are centralised, Ireland got it the same day France and Germany did.

That's the good news. The awkward news is that an approval and a box on a pharmacy shelf are two very different things, and in Ireland there's a third thing again, which is whether anyone other than you pays for it. Here's what the decision does, what the trial actually found, and what an Irish reader can reasonably expect next.

What actually happened, and when

Two dates matter. On 22 May 2026 the EMA's Committee for Medicinal Products for Human Use recommended extending Wegovy's existing marketing authorisation to cover an oral formulation. On 15 July 2026 the European Commission adopted that recommendation and granted the authorisation.

The second date is the one that counts legally. A centralised EU marketing authorisation is valid in every member state from the day the Commission grants it, so the tablet is authorised in Ireland now. the HPRA doesn't run a separate Irish approval for medicines that go through the centralised route. Its job here is oversight and safety monitoring once a product is on the market.

The same decision also cleared a 7.2 mg Wegovy injection in a single-dose pen, which is a higher dose than the 2.4 mg most people currently take. Different product, different conversation, but it landed in the same announcement, which is why some coverage in July muddled the two.

What the tablet is

It's semaglutide. The same molecule as the weekly Wegovy injection, taken as a 25 mg tablet once a day instead. Not a new drug, not a different mechanism, and not a lower dose in any meaningful sense: oral semaglutide is absorbed far less efficiently than an injection, which is why the milligram number looks so much bigger for what ends up being a comparable effect.

One restriction is worth knowing. The Wegovy injection is authorised in the EU from age 12. The tablets are for adults only. If you're reading this for a teenager, the tablet isn't the answer.

What the trial showed

The approval rests on a phase 3 trial called OASIS 4, published in the New England Journal of Medicine. 307 adults took part. They either had obesity, or were overweight with at least one weight-related condition, and none of them had diabetes. Two out of every three got the 25 mg tablet and one got placebo, and everyone got diet and activity advice on top.

Over 64 weeks:

• The tablet group lost 13.61% of body weight on average. The placebo group lost 2.18%.
• 76.3% of people on the tablet lost at least 5% of their body weight, against 30.5% on placebo.
• Gastrointestinal side effects were the common ones, and they were common: 74.0% of the tablet group reported one, against 42.2% on placebo. Nausea, diarrhoea, constipation, abdominal pain, indigestion and vomiting, mostly early on.

To put 13.61% in a body you can picture: someone starting at 95 kg would be around 82 kg after 64 weeks if they landed on the average. The average is not a promise, and a trial average hides a wide spread in both directions.

Why you will see two different numbers

If you read the EMA statement you'll see 13.61%. If you read Novo Nordisk's announcement you'll see roughly 17%. Neither is wrong, and neither is a typo.

They're two ways of counting the same trial. The regulator's figure counts everyone who was randomised, including the people who stopped the medicine partway through for whatever reason. The company's figure describes what happened to people who stayed on it. Trials report both on purpose, because they answer different questions: one is "what happens if I try this", and the other is "what happens if this suits me and I keep going".

The lower number is the more honest one to plan around, because you don't know yet which group you'll be in.

The routine it demands

This is the part that gets buried, and it's the part most likely to decide whether the tablet suits you. Per the EMA, Wegovy tablets are taken:

• once daily, on an empty stomach
• after at least eight hours of fasting
• then nothing to eat, nothing to drink and no other medicines for the following 30 minutes

Eight hours without food is easy, because most of it happens while you're asleep. The 30 minutes afterwards is the friction. No tea. No coffee. No thyroid tablet, no blood pressure tablet, nothing. Every single morning, or absorption drops and you're taking a tablet that isn't doing much.

Compare that with the injection: one jab a week, any time of day, food or no food. People assume the pill must be the easier option because needles are frightening. For plenty of people it's the opposite, and it's worth being honest with yourself about your actual mornings before you decide.

Pill or injection?

Both are semaglutide, so this isn't a question about which drug is stronger. It's a question about which one you'll actually keep taking.

• The tablet suits you if needles are a genuine barrier, your mornings are predictable, and you don't take other medicines that need to go in early.
• The injection suits you if your mornings are chaotic, you take other tablets on waking, or the idea of remembering something every single day is exactly the thing that's defeated you before.
• Neither is a decision to make alone. Which one you're prescribed, and whether either is appropriate, is a conversation with your GP or prescriber.

One thing that does transfer either way is tracking. Whatever form you take it in, the useful signal is the same: weight over weeks rather than days, what you actually ate, and when the side effects landed relative to a dose change. Our side effect timeline and titration planner both work the same in Ireland as anywhere else.

Where Ireland stands

Three separate questions get run together here, so let's take them apart.

Is it approved? Yes, since 15 July 2026.

Can you get it? Not yet. Novo Nordisk has said it plans to launch the tablet in more countries in the second half of 2026 and hasn't named Ireland. No Irish pharmacy has published a price. We're not going to guess at one, because a made-up number is worse than no number.

Will the HSE pay for it? The EMA says plainly that price and reimbursement are decided by each member state. For a realistic sense of the timeline, look at what's happened with the Wegovy injection. Novo Nordisk applied to the HSE for reimbursement on 19 March 2025. The rapid review finished that May and recommended a full assessment. The full submission arrived in February 2026, the NCPE sent back a preliminary review in May 2026, and as of July 2026 the assessment status is still "awaiting response from applicant". Sixteen months in, no decision.

Tirzepatide is a little further along and no closer to your pocket. The NCPE finished assessing Mounjaro for weight management on 3 December 2025 and said it could be considered for reimbursement if cost-effectiveness improves, which in plain terms means at a lower price. In February 2026 the HSE told the Dáil it had met Eli Lilly and was waiting on a proposal.

So the practical position in Ireland today: Saxenda is the only weight-management medicine reimbursed on the community schemes, and only under a managed access protocol with tight criteria. Everything else is private pay. There's more detail, with the price lists and the documents behind them, on our Irish GLP-1 prices and access page.

What to do with this now

If you're already on the Wegovy injection and doing well on it, this changes nothing today. Don't switch on the strength of a headline, and don't stop anything to wait for a tablet with no launch date.

If you're considering treatment for the first time, the sequence is the same as it was: talk to your GP or a prescriber about whether medication is appropriate at all, what the criteria are, and what it will cost you privately. The tablet becoming available later doesn't change whether you meet the criteria now.

And if you're waiting specifically because of the needle, that's a reasonable thing to wait for. Just go in knowing what the tablet asks of your mornings.